Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Azacitidine + Narazaciclib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Azacitidine | Vidaza | azacytidine|CC-486|5-azacytidine|5-AC|U-18496|Onureg | DNMT inhibitor (Pan) 5 | Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome and Onureg (azacitidine) is FDA approved for use in continued treatment of acute myeloid leukemia(FDA.gov). |
| Narazaciclib | 7X|ON-123300|ON 123300|ON123300 | CDK4 Inhibitor 18 NUAK1 Inhibitor 3 | Narazaciclib (ON123300) inhibits CDK4 and ARK5 (NUAK1), resulting in decreased downstream signaling and increased tumor cell death (PMID: 24417566, PMID: 26873845). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Azacitidine + Narazaciclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, addition of Vidaza (azacitidine) enhanced the anti-tumor activity of Narazaciclib (ON123300) in a cell line xenograft model of acute myeloid leukemia harboring FLT3-ITD (PMID: 38641704). | 38641704 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|